Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
SAN DIEGO, April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (t
PR NewswireApr 30 08:00 ET
Regulus Files to Sell 62.5M Shares of Common Stock for Holders
Seeking AlphaApr 9 17:06 ET
Buy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development Milestones
TipRanksMar 25 06:26 ET
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Yahoo FinanceMar 23 05:33 ET
Regulus Therapeutics: Oversubscribed $100M Private Placement to Extend Cash Runway Into 1H of 2026 >RGLS
Regulus Therapeutics: Oversubscribed $100M Private Placement to Extend Cash Runway Into 1H of 2026 >RGLS
Dow JonesMar 21 16:13 ET
Express News | Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate
Moomoo 24/7Mar 21 16:08 ET
Regulus Therapeutics 4Q Loss $8.06M >RGLS
Regulus Therapeutics 4Q Loss $8.06M >RGLS
Dow JonesMar 21 16:05 ET
Press Release: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates PR Newswire SAN DIEGO, March 21, 2024 Positive topline data from the second cohort of patients in
Dow JonesMar 21 16:05 ET
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating
Regulus Therapeutics (RGLS) has an average outperform rating and price target range of $3 to $11, according to analysts polled by Capital IQ. Price: 2.23, Change: -0.13, Percent Change: -5.51
MT NewswiresMar 19 10:15 ET
Regulus Therapeutics Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity
Regulus Therapeutics Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity
Dow JonesMar 19 08:22 ET
Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity
Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow JonesMar 19 08:22 ET
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11
Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics with a Buy and lowers the price target from $12 to $11.
Analyst UpgradesMar 19 08:12 ET
Regulus Therapeutics Initiated at Outperform by Leerink Partners
Regulus Therapeutics Initiated at Outperform by Leerink Partners
Dow JonesMar 18 08:35 ET
Express News | Leerink Partners Initiates Coverage On Regulus Therapeutics With Outperform Rating, Announces Price Target of $6
Moomoo 24/7Mar 18 08:25 ET
Buy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment Data
TipRanksMar 18 08:15 ET
Express News | HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Moomoo 24/7Mar 18 07:01 ET
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Yahoo FinanceMar 14 12:07 ET
Express News | Regulus Therapeutics Shares Are Trading Higher After Wells Fargo Maintained an Equal-Weight Rating on the Stock and Raised Its Price Target From $2 to $3
Moomoo 24/7Mar 13 13:58 ET
Regulus (RGLS) Up 71% on Topline Data From Kidney Disease Study
Yahoo FinanceMar 13 12:09 ET
Wells Fargo Maintains Equal-Weight on Regulus Therapeutics, Raises Price Target to $3
Wells Fargo analyst Jim Birchenough maintains Regulus Therapeutics (NASDAQ:RGLS) with a Equal-Weight and raises the price target from $2 to $3.
BenzingaMar 13 06:53 ET
No Data
No Data